Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01192763
Other study ID # NCI-2011-02523
Secondary ID NCI-2011-02523CD
Status Terminated
Phase Phase 1
First received August 31, 2010
Last updated September 27, 2013
Start date August 2010

Study information

Verified date September 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects of RO4929097 before surgery in treating patients with pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Giving RO4929097 before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the effects of neoadjuvant gamma-secretase inhibitor RO4929097 on Notch inhibition via interrogation of Hes-1 expression in patients with pancreatic cancer.

SECONDARY OBJECTIVES:

I. To evaluate the effects of this regimen on pancreatic cancer stem cell self-renewal and tumorigenesis as compared to pancreatic stem cells from controls (patients who do not receive treatment).

II. To evaluate the safety of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.

After completion of study therapy, patients are followed up every 6 months for 1 year.


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed pancreatic adenocarcinoma

- T1-3, N0-1, and M0 disease

- Surgically resectable disease confirmed by a surgeon experienced in pancreatic surgery

- No borderline resectable disease defined as any of the following:

- Tumors with severe unilateral or bilateral SMV/portal involvement impingement

- Abutment (or) encasement of hepatic artery

- SMA or celiac encasement (or) presence of SMV occlusion by tumor

- No metastatic disease

- ECOG performance status 0-1

- Life expectancy > 6 months

- WBC = 3,000/mm³

- ANC = 1,500/mm³

- Platelet count = 100,000/mm³

- Hemoglobin = 9 g/dL

- Total bilirubin = 2 mg/dL

- AST and ALT = 2.5 times upper limit of normal

- Creatinine = 2 mg/dL

- Calcium, magnesium, phosphorous, and potassium normal

- Negative pregnancy test

- Not pregnant or nursing

- Fertile patients must use effective barrier-method contraception 4 weeks before, during, and for = 12 months after completion of treatment

- Able to swallow tablets

- No malabsorption syndrome or other condition that would interfere with intestinal absorption

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in the study

- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia despite adequate electrolyte supplementation

- Grade 1 hyponatremia with sodium = 131 mg/dL is permissible

- No uncontrolled intercurrent illness including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia other than chronic

- Stable atrial fibrillation

- Psychiatric illness/social situations that would limit compliance with study requirements

- No baseline QTcF > 450 msec (male) or QTcF > 470 msec (female)

- Patients with a prior cancer with evidence of active cancer are excluded from this study

- Patients with a prior cancer are permitted to enter this study as long as there is no documented evidence of active malignancy

- No uncontrolled electrolyte abnormalities including hypocalcemia, hypomagnesemia, and hypokalemia

- No symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmias

- No requirement for antiarrhythmics or other medications known to prolong QTc

- No other concurrent anticancer agents or therapies

- Recovered to < grade 2 toxicity related to prior therapy

- No prior chemotherapy or radiotherapy for pancreatic cancer

- No other concurrent investigational agents

- No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®), ketoconazole, or grapefruit juice

- No concurrent strong inducers or inhibitors of CYP3A4

- No concurrent combination antiretroviral therapy for HIV-positive patients

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
gamma-secretase/Notch signalling pathway inhibitor RO4929097
Given orally
Other:
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
Procedure:
neoadjuvant therapy

therapeutic conventional surgery


Locations

Country Name City State
United States Tower Cancer Research Foundation Beverly Hills California
United States University of Chicago Comprehensive Cancer Center Chicago Illinois
United States City of Hope Medical Center Duarte California
United States Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Fort Wayne Indiana
United States Illinois CancerCare-Peoria Peoria Illinois
United States Central Illinois Hematology Oncology Center Springfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Notch activity (expression of Hes-1) Summarized as a binary endpoint for both the RO4929097 population and the stage-matched controls by the proportion and 95% exact binomial confidence interval. Up to day 3 (of course 1) No
Primary Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Toxicity will be determined with a 95% exact binomial confidence interval. Up to 1 year Yes
Secondary Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS Up to day 3 (of course 1) No
See also
  Status Clinical Trial Phase
Completed NCT01064622 - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Phase 1/Phase 2
Completed NCT00375310 - Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer Phase 1
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00020345 - Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas Phase 2
Completed NCT03871959 - Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma Phase 1
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Withdrawn NCT01401387 - Pancreatic Enzyme Suppletion in Pancreatic Cancer Phase 4
Completed NCT01447732 - Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01232829 - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00735917 - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04543071 - Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma Phase 2
Terminated NCT03490760 - Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas Phase 2
Completed NCT01068327 - Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Phase 1
Recruiting NCT05419479 - Switch Maintenance in Pancreatic Phase 1/Phase 2
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT00026104 - Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer Phase 2
Terminated NCT01318642 - Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas Phase 2
Completed NCT00474812 - Dasatinib in Treating Patients With Metastatic Pancreatic Cancer Phase 2